Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Ann Oncol
    August 2021
  1. EMENS LA, Adams S, Barrios CH, Dieras V, et al
    First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
    Ann Oncol. 2021;32:983-993.
    >> Share

  2. VOORWERK L, Kok M
    'IMpassionate conflicts' in immunotherapy trials for metastatic triple-negative breast cancer.
    Ann Oncol. 2021;32:947-949.
    >> Share

    July 2021
  3. LOI S, Michiels S, Adams S, Loibl S, et al
    The journey of tumor infiltrating lymphocytes (TIL) as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
    Ann Oncol. 2021 Jul 23. pii: S0923-7534(21)02185.
    >> Share

  4. BURSTEIN HJ, Curigliano G, Thurlimann B, Weber WP, et al
    CUSTOMIZING LOCAL AND SYSTEMIC THERAPIES FOR WOMEN WITH EARLY BREAST CANCER: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.
    Ann Oncol. 2021 Jul 6. pii: S0923-7534(21)02104.
    >> Share

  5. MILES D, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
    Ann Oncol. 2021 Jul 2. pii: S0923-7534(21)02105.
    >> Share

  6. MILES D, Gligorov J, Andre F, Cameron D, et al
    Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Ann Oncol. 2021 Jul 1. pii: S0923-7534(21)02026.
    >> Share

    June 2021
  7. BARDIA A, Tolaney SM, Punie K, Loirat D, et al
    Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
    Ann Oncol. 2021 Jun 8. pii: S0923-7534(21)02047.
    >> Share

    May 2021
  8. PICCART MJ, Kalinsky K, Gray R, Barlow WE, et al
    Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.
    Ann Oncol. 2021 May 31. pii: S0923-7534(21)02029.
    >> Share

  9. MAMOUNAS EP
    Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study.
    Ann Oncol. 2021 May 28. pii: S0923-7534(21)02027.
    >> Share

  10. SLAMON DJ, Neven P, Chia S, Jerusalem G, et al
    Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.
    Ann Oncol. 2021 May 15. pii: S0923-7534(21)01553.
    >> Share

  11. GAO JJ, Krol D, Narayan P, Cardoso F, et al
    Bringing Safe and Effective Therapies to Premenopausal Women with Breast Cancer: Efforts to Broaden Eligibility Criteria.
    Ann Oncol. 2021 May 12. pii: S0923-7534(21)01556.
    >> Share

    April 2021
  12. MAMOUNAS EP, Untch M, Mano MS, Huang CS, et al
    Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE.
    Ann Oncol. 2021 Apr 28. pii: S0923-7534(21)01168.
    >> Share

    February 2021
  13. DU L, Yau C, Brown-Swigart L, Gould R, et al
    Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.
    Ann Oncol. 2021 Feb 19. pii: S0923-7534(21)00128.
    >> Share

  14. AGOSTINETTO E, Ignatiadis M
    Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: Lessons from the PEARL study.
    Ann Oncol. 2021 Feb 8. pii: S0923-7534(21)00106.
    >> Share

  15. BRUFSKY A, Kim SB, Zvirbule Z, Eniu A, et al
    A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
    Ann Oncol. 2021 Feb 1. pii: S0923-7534(21)00093.
    >> Share

  16. MATIKAS A, Foukakis T
    SOLAR1s: alpelisib returns to earth?
    Ann Oncol. 2021;32:129-132.
    >> Share

  17. VANACKER H, Cassier PA, Bachelot T
    The complex balance of PI3K inhibition.
    Ann Oncol. 2021;32:127-128.
    >> Share

    January 2021
  18. MONTOPOLI M, Zorzi M, Cocetta V, Prayer-Galetti T, et al
    Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy.
    Ann Oncol. 2021 Jan 29. pii: S0923-7534(21)00097.
    >> Share

  19. CARIOLI G, Malvezzi M, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer.
    Ann Oncol. 2021 Jan 21. pii: S0923-7534(21)00014.
    >> Share

  20. DENKERT C, Untch M, Benz S, Schneeweiss A, et al
    Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy.
    Ann Oncol. 2021 Jan 5. pii: S0923-7534(20)43224.
    >> Share

    December 2020
  21. LOHMANN AE, Goodwin PJ
    Diabetes, metformin and breast cancer: a tangled web.
    Ann Oncol. 2020 Dec 31. pii: S0923-7534(20)43222.
    >> Share

  22. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
    Ann Oncol. 2020 Dec 29. pii: S0923-7534(20)43221.
    >> Share

  23. PARK YM, Bookwalter DB, O'Brien KM, Jackson CL, et al
    A Prospective Study of Type 2 diabetes, metformin use, and risk of breast cancer.
    Ann Oncol. 2020 Dec 19. pii: S0923-7534(20)43214.
    >> Share

  24. FRANZOI MA, Romano E, Piccart M
    Immunotherapy for early breast cancer: too soon, too superficial, or just right?
    Ann Oncol. 2020 Dec 8. pii: S0923-7534(20)43198.
    >> Share

  25. GRINSHPUN A, Moss J, Uziely B
    Key Role for Liquid Biopsy in the Elimination of Breast Cancer Surgery following Neoadjuvant Therapy.
    Ann Oncol. 2020 Dec 7. pii: S0923-7534(20)43201.
    >> Share

  26. AMIRI-KORDESTANI L, Xie D, Tolaney SM, Bloomquist E, et al
    A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials.
    Ann Oncol. 2020;31:1704-1708.
    >> Share

    November 2020
  27. ANDRE F, Ciruelos EM, Juric D, Loibl S, et al
    Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.
    Ann Oncol. 2020 Nov 24. pii: S0923-7534(20)43166.
    >> Share

  28. EIKESDAL HP, Yndestad S, Elzawahry A, Llop-Guevara A, et al
    Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.
    Ann Oncol. 2020 Nov 23. pii: S0923-7534(20)43164.
    >> Share

  29. MAGBANUA MJM, Swigart LB, Wu HT, Hirst GL, et al
    Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Ann Oncol. 2020 Nov 21. pii: S0923-7534(20)43162.
    >> Share

  30. XU B, Sun T, Zhang Q, Zhang P, et al
    Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase 3 randomised controlled trial.
    Ann Oncol. 2020 Nov 11. pii: S0923-7534(20)43130.
    >> Share

  31. DENT S, Cortes J, Im YH, Dieras V, et al
    Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
    Ann Oncol. 2020 Nov 10. pii: S0923-7534(20)43124.
    >> Share

  32. PUSZTAI L
    PARP inhibition in homologous recombination deficient early stage breast cancer.
    Ann Oncol. 2020 Nov 9. pii: S0923-7534(20)43128.
    >> Share

    October 2020
  33. FASCHING PA, Link T, Hauke J, Seither F, et al
    Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
    Ann Oncol. 2020 Oct 21. pii: S0923-7534(20)42963.
    >> Share

  34. SIPOS O, Tovey H, Quist J, Haider S, et al
    Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in Triple Negative Breast Cancer: the TNT trial.
    Ann Oncol. 2020 Oct 21. pii: S0923-7534(20)42977.
    >> Share

  35. STECKLEIN SR, Sharma P
    Last but not Least: Antibody-Drug Conjugates in Hormone Receptor-Positive Metastatic Breast Cancer.
    Ann Oncol. 2020 Oct 7. pii: S0923-7534(20)42492.
    >> Share

  36. LIN NU
    Reevaluating the role of antibody-drug conjugates in the treatment of patients with brain metastases.
    Ann Oncol. 2020;31:1279-1281.
    >> Share

    September 2020
  37. GRINDA T, Delaloge S
    Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
    Ann Oncol. 2020 Sep 29. pii: S0923-7534(20)42468.
    >> Share

  38. CARDOSO F, Paluch-Shimon S, Senkus E, Curigliano G, et al
    5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)(dagger).
    Ann Oncol. 2020 Sep 23. pii: S0923-7534(20)42460.
    >> Share

  39. KALINSKY K, Diamond JR, Vahdat LT, Tolaney SM, et al
    Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial.
    Ann Oncol. 2020 Sep 15. pii: S0923-7534(20)42445.
    >> Share

  40. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Erratum to "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology 30; 2019: 1194-1220.
    Ann Oncol. 2020 Sep 7. pii: S0923-7534(20)42223.
    >> Share

  41. KARN T, Denkert C, Weber KE, Holtrich U, et al
    Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
    Ann Oncol. 2020;31:1216-1222.
    >> Share

    August 2020
  42. LITTON JK, Hurvitz SA, Mina LA, Rugo HS, et al
    Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    Ann Oncol. 2020 Aug 20. pii: S0923-7534(20)42106.
    >> Share

  43. MAYER EL, Abramson V, Jankowitz R, Falkson C, et al
    TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
    Ann Oncol. 2020 Aug 13. pii: S0923-7534(20)42061.
    >> Share

    July 2020
  44. LUEN SJ, Asher R, Lee CK, Savas P, et al
    Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
    Ann Oncol. 2020 Jul 8. pii: S0923-7534(20)39934.
    >> Share

  45. MONTEMURRO F, Delaloge S, Barrios CH, Wuerstlein R, et al
    Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.
    Ann Oncol. 2020 Jul 4. pii: S0923-7534(20)39930.
    >> Share

  46. LYMAN GH, Kuderer NM
    Personalized cancer supportive care in COVID-19 era.
    Ann Oncol. 2020;31:835-837.
    >> Share

    May 2020
  47. HEIL J, Pfob A
    Patients should be the tipping point of individualizing breast cancer surgery.
    Ann Oncol. 2020 May 28. pii: S0923-7534(20)39844.
    >> Share

  48. BARCENAS CH, Hurvitz SA, Di Palma JA, Bose R, et al
    Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.
    Ann Oncol. 2020 May 25. pii: S0923-7534(20)39833.
    >> Share

  49. METZGER O, Leone JP, Li T, Tan-Wasielewski Z, et al
    Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
    Ann Oncol. 2020 May 24. pii: S0923-7534(20)39835.
    >> Share

  50. HILBERS FS, Aftimos P
    Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all?
    Ann Oncol. 2020 May 15. pii: S0923-7534(20)39818.
    >> Share

  51. RUGO HS, Andre F, Yamashita T, Cerda H, et al
    Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer.
    Ann Oncol. 2020 May 13. pii: S0923-7534(20)39798.
    >> Share

  52. CARIOLI G, Bertuccio P, Boffetta P, Levi F, et al
    European cancer mortality predictions for the year 2020 with a focus on prostate cancer.
    Ann Oncol. 2020;31:650-658.
    >> Share

    April 2020
  53. ROSS DS, Liu B, Schram AM, Razavi P, et al
    Enrichment of Kinase Fusions in ESR1 Wild Type, Metastatic Breast Cancer Revealed by a Systematic Analysis of 4,854 Patients.
    Ann Oncol. 2020 Apr 26. pii: S0923-7534(20)39306.
    >> Share

  54. CABALLERO C, Piccart M
    Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want.
    Ann Oncol. 2020 Apr 25. pii: S0923-7534(20)39307.
    >> Share

  55. CLEMONS M, Fergusson D, Simos D, Mates M, et al
    A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.
    Ann Oncol. 2020 Apr 20. pii: S0923-7534(20)39296.
    >> Share

    March 2020
  56. PALUCH-SHIMON S, Cardoso F, Partridge AH, Abulkhair O, et al
    ESO-ESMO 4(rd) International Consensus Guidelines for Breast Cancer in Young Women (BCY4).
    Ann Oncol. 2020 Mar 18. pii: S0923-7534(20)36363.
    >> Share

  57. GRELLETY T, Peyraud F, Sevenet N, Tredan O, et al
    Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.
    Ann Oncol. 2020 Mar 17. pii: S0923-7534(20)36362.
    >> Share

  58. VAN DONGEN M, Kok M
    Mise en place: towards neoadjuvant chemo-immunotherapy for early triple-negative breast cancer.
    Ann Oncol. 2020 Mar 11. pii: S0923-7534(20)36075.
    >> Share

  59. MURPHY N, Knuppel A, Papadimitriou N, Martin RM, et al
    Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with approximately 430 000 women.
    Ann Oncol. 2020 Mar 9. pii: S0923-7534(20)36019.
    >> Share

  60. MAVROUDIS D, Saloustros E, Malamos N, Kakolyris S, et al
    Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volu
    Ann Oncol. 2020;31:444-445.
    >> Share

  61. MOSS J, Zick A, Grinshpun A, Carmon E, et al
    Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer.
    Ann Oncol. 2020;31:395-403.
    >> Share

  62. BARROSO-SOUSA R, Jain E, Cohen O, Kim D, et al
    Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
    Ann Oncol. 2020;31:387-394.
    >> Share

  63. MOSELE F, Stefanovska B, Lusque A, Tran Dien A, et al
    Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Ann Oncol. 2020;31:377-386.
    >> Share

  64. DI COSIMO S, Appierto V, Silvestri M, Ortolan E, et al
    Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast.
    Ann Oncol. 2020;31:435-437.
    >> Share

  65. YVER A, Agatsuma T, Soria JC
    The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.
    Ann Oncol. 2020;31:430-434.
    >> Share

  66. KURZROCK R, Bowles DW, Kang H, Meric-Bernstam F, et al
    Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
    Ann Oncol. 2020;31:412-421.
    >> Share

    February 2020
  67. BJELIC-RADISIC V, Cardoso F, Cameron D, Brain E, et al
    Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45: Ann Oncol 2020; Volume 31, Issue 2, Pages 283-288.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36026.
    >> Share

  68. ADAMS S, Dieras V, Barrios CH, Winer EP, et al
    Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36038.
    >> Share

  69. WAKS AG, Cohen O, Kochupurakkal B, Kim D, et al
    Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055.
    >> Share

  70. SCHMID P, Salgado R, Park YH, Munoz-Couselo E, et al
    Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
    Ann Oncol. 2020 Feb 14. pii: S0923-7534(20)36032.
    >> Share

  71. GRYNBERG M, Mayeur Le Bras A, Hesters L, Gallot V, et al
    First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer.
    Ann Oncol. 2020 Feb 12. pii: S0923-7534(20)35923.
    >> Share

  72. BJELIC-RADISIC V, Cardoso F, Cameron D, Brain E, et al
    An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45.
    Ann Oncol. 2020;31:283-288.
    >> Share

    January 2020
  73. PARK YH, Senkus-Konefka E, Im SA, Pentheroudakis G, et al
    Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
    Ann Oncol. 2020 Jan 16. pii: S0923-7534(20)35929.
    >> Share

  74. HEIL J, Kuerer HM, Pfob A, Rauch G, et al
    Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges.
    Ann Oncol. 2020;31:61-71.
    >> Share

    December 2019
  75. BRANDAO M, Caparica R, Eiger D, de Azambuja E, et al
    Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
    Ann Oncol. 2019;30.
    >> Share

  76. VERRET B, Cortes J, Bachelot T, Andre F, et al
    Efficacy of PI3K inhibitors in advanced breast cancer.
    Ann Oncol. 2019;30.
    >> Share

  77. VASAN N, Toska E, Scaltriti M
    Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Ann Oncol. 2019;30.
    >> Share

  78. VASAN N, Toska E, Scaltriti M
    Overview of the relevance of PI3K pathway in HR-positive breast cancer.
    Ann Oncol. 2019;30 Suppl 10:x3-x11.
    >> Share

  79. BRANDAO M, Caparica R, Eiger D, de Azambuja E, et al
    Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
    Ann Oncol. 2019;30 Suppl 10:x27-x42.
    >> Share

  80. VERRET B, Cortes J, Bachelot T, Andre F, et al
    Efficacy of PI3K inhibitors in advanced breast cancer.
    Ann Oncol. 2019;30 Suppl 10:x12-x20.
    >> Share

  81. PARK YH, Lee SJ, Cho EY, La Choi Y, et al
    Clinical relevance of TNM staging system according to breast cancer subtypes.
    Ann Oncol. 2019;30:2011.
    >> Share

  82. DUBSKY P, Montagna G, Ritter M
    Lymphocyte infiltration predicts survival in chemotherapy-naive, triple-negative breast cancer and identifies patients with intrinsically good prognosis: have we been bringing owls to Athens?
    Ann Oncol. 2019;30:1849-1850.
    >> Share

    November 2019
  83. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2019;30:1842.
    >> Share

  84. FERREIRA AR, Di Meglio A, Pistilli B, Gbenou AS, et al
    Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
    Ann Oncol. 2019;30:1784-1795.
    >> Share

  85. BARTLETT JMS, Sgroi DC, Treuner K, Zhang Y, et al
    Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
    Ann Oncol. 2019;30:1776-1783.
    >> Share

  86. BRANDAO M, Coens C, Ignatiadis M
    Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?
    Ann Oncol. 2019;30:1677-1681.
    >> Share

    October 2019
  87. DUBSKY P, Montagna G, Ritter M
    Lymphocyte infiltration predicts survival in chemotherapy-naive, triple negative breast cancer, and identifies patients with intrinsically good prognosis: Have we been bringing owls to Athens?
    Ann Oncol. 2019 Oct 18. pii: 5593649. doi: 10.1093.
    >> Share

  88. FERREIRA AR, Di Meglio A, Pistilli B, Gbenou AS, et al
    Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.
    Ann Oncol. 2019 Oct 8. pii: 5583691. doi: 10.1093.
    >> Share

  89. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019;30:1674.
    >> Share

  90. BURSTEIN HJ, Curigliano G, Loibl S, Dubsky P, et al
    Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
    Ann Oncol. 2019;30:1541-1557.
    >> Share

  91. ARNEDOS M, Gligorov J
    St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients' overtreatment and breaking the bank?
    Ann Oncol. 2019;30:1533-1535.
    >> Share

    August 2019
  92. BARTLETT JMS, Sgroi DC, Treuner K, Zhang Y, et al
    Breast Cancer Index and Prediction of Benefit from Extended Endocrine Therapy in Breast Cancer Patients Treated in the Adjuvant Tamoxifen - To Offer More? (aTTom) Trial.
    Ann Oncol. 2019 Aug 28. pii: 5555808. doi: 10.1093.
    >> Share

  93. ARNEDOS M, Gligorov J
    St Gallen international consensus guidelines in early breast cancer: Experts to prevent patients' overtreatment and breaking the bank?
    Ann Oncol. 2019 Aug 27. pii: 5555359. doi: 10.1093.
    >> Share

  94. PARK YH, Lee SJ, Cho EY, La Choi Y, et al
    Clinical relevance of TNM staging system according to breast cancer subtypes.
    Ann Oncol. 2019 Aug 13. pii: 5549411. doi: 10.1093.
    >> Share

  95. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2019 Aug 13. pii: 5548997. doi: 10.1093.
    >> Share

  96. SRINIVASALU VK, Susan A, Philip A, Jose WM, et al
    147P Clinical significance of BCL-2 with basal and non-basal triple negative breast cancer (TNBC).
    Ann Oncol. 2019 Aug 2. pii: 5543073. doi: 10.1093.
    >> Share

  97. BURSTEIN HJ, Curigliano G, Loibl S, Dubsky P, et al
    Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019.
    Ann Oncol. 2019 Aug 2. pii: 5543097. doi: 10.1093.
    >> Share

  98. SRINIVASALU VK, Susan A, Jose WM, Philip A, et al
    41P Prognostic significance of BCL-2 expression in triple negative breast cancer (TNBC).
    Ann Oncol. 2019 Aug 2. pii: 5543072. doi: 10.1093.
    >> Share

    July 2019
  99. LOI S
    The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine.
    Ann Oncol. 2019 Jul 9. pii: 5530161. doi: 10.1093.
    >> Share

  100. CURIGLIANO G, Burstein HJ, P Winer E, Gnant M, et al
    Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017".
    Ann Oncol. 2019;30:1181.
    >> Share

  101. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    Corrections to "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab".
    Ann Oncol. 2019;30:1180.
    >> Share

  102. CORTES J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, et al
    Corrections to "Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis".
    Ann Oncol. 2019;30:1179.
    >> Share

  103. PASCUAL J, Turner NC
    Targeting the PI3-kinase pathway in triple-negative breast cancer.
    Ann Oncol. 2019;30:1051-1060.
    >> Share

  104. MATIKAS A, Foukakis T, Swain S, Bergh J, et al
    Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
    Ann Oncol. 2019;30:1044-1050.
    >> Share

  105. FOULKES WD, Polak P
    Journey's end: the quest for BRCA-like hereditary breast cancer genes is nearly over.
    Ann Oncol. 2019;30:1023-1025.
    >> Share

    June 2019
  106. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jun 24. pii: 5522519. doi: 10.1093.
    >> Share

  107. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2019 Jun 4. pii: 5499075. doi: 10.1093.
    >> Share

    May 2019
  108. OLIVEIRA M, Saura C, Nuciforo P, Calvo I, et al
    FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
    Ann Oncol. 2019 May 30. pii: 5506637. doi: 10.1093.
    >> Share

  109. LOIBL S, Untch M, Burchardi N, Huober J, et al
    A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study.
    Ann Oncol. 2019 May 16. pii: 5490226. doi: 10.1093.
    >> Share

  110. FOULKES WD, Polak P
    Journey's End: the quest for BRCA-like hereditary breast cancer genes is nearly over.
    Ann Oncol. 2019 May 15. pii: 5489599. doi: 10.1093.
    >> Share

  111. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    Reply to the Letter to the Editor: "European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al." by J. Marsden, H. Hamoda, On behalf of the British Menopause Society Medical Advisory Council.
    Ann Oncol. 2019 May 9. pii: 5487409. doi: 10.1093.
    >> Share

  112. MARSDEN J, Hamoda H
    European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al. (Ann Oncol 2019; 30: doi.org/10.1093/annonc/mdz051).
    Ann Oncol. 2019 May 9. pii: 5482565. doi: 10.1093.
    >> Share

  113. PASCUAL J, Turner NC
    Targeting the PI3-kinase pathway in triple negative breast cancer.
    Ann Oncol. 2019 May 3. pii: 5485241. doi: 10.1093.
    >> Share

  114. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2019 with focus on breast cancer.
    Ann Oncol. 2019;30:781-787.
    >> Share

  115. TURNER NC, Alarcon E, Armstrong AC, Philco M, et al
    BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK
    Ann Oncol. 2019;30:774-780.
    >> Share

  116. BACHELOT T, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Ann Oncol. 2019;30:766-773.
    >> Share

    April 2019
  117. DE AZAMBUJA E, Piccart-Gebhart M
    ER+/HER2+ breast cancer: are we really de-escalating?
    Ann Oncol. 2019 Apr 16. pii: 5472336. doi: 10.1093.
    >> Share

  118. MATIKAS A, Foukakis T, Swain S, Bergh J, et al
    Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
    Ann Oncol. 2019 Apr 9. pii: 5435960. doi: 10.1093.
    >> Share

  119. MARRA A, Curigliano G
    T cell Bispecific Antibodies to Bypass MHC Class I Loss in Breast Cancer.
    Ann Oncol. 2019 Apr 2. pii: 5425459. doi: 10.1093.
    >> Share

  120. DELALOGE S, Cella D, Ye Y, Buyse M, et al
    Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
    Ann Oncol. 2019;30:567-574.
    >> Share

  121. ROBSON ME, Tung N, Conte P, Im SA, et al
    OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Ann Oncol. 2019;30:558-566.
    >> Share

    March 2019
  122. DIOSSY M, Reiniger L, Sztupinszki Z, Krzystanek M, et al
    Corrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
    Ann Oncol. 2019 Mar 30. pii: 5423828. doi: 10.1093.
    >> Share

  123. MESSAOUDENE M, Mourikis TP, Michels J, Fu Y, et al
    T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.
    Ann Oncol. 2019 Mar 29. pii: 5423181. doi: 10.1093.
    >> Share

  124. VEERARAGHAVAN J, De Angelis C, Mao R, Wang T, et al
    A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
    Ann Oncol. 2019 Mar 23. pii: 5418530. doi: 10.1093.
    >> Share

  125. MALVEZZI M, Carioli G, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2019 with focus on breast cancer.
    Ann Oncol. 2019 Mar 19. pii: 5382368. doi: 10.1093.
    >> Share

  126. HREBIEN S, Citi V, Garcia-Murillas I, Cutts R, et al
    Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial.
    Ann Oncol. 2019 Mar 12. pii: 5376514. doi: 10.1093.
    >> Share

  127. TURNER NC, Alarcon E, Armstrong AC, Philco M, et al
    BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK
    Ann Oncol. 2019 Mar 12. pii: 5376517. doi: 10.1093.
    >> Share

    February 2019
  128. BACHELOT T, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Ann Oncol. 2019 Feb 23. pii: 5364015. doi: 10.1093.
    >> Share

  129. GUARNERI V, Dieci MV, Bisagni G, Frassoldati A, et al
    De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study.
    Ann Oncol. 2019 Feb 18. pii: 5332974. doi: 10.1093.
    >> Share

  130. TELLI ML, Vinayak S
    Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way.
    Ann Oncol. 2019 Feb 7. pii: 5308591. doi: 10.1093.
    >> Share

  131. YAP YS, Ho D, Ng RC, Chan CH, et al
    27PDetection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens.
    Ann Oncol. 2019;30.
    >> Share

  132. SON S, Kim H, Shin I
    23PMatricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer.
    Ann Oncol. 2019;30.
    >> Share

  133. KIM H, Son S
    22PTherapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer.
    Ann Oncol. 2019;30.
    >> Share

  134. LUEN SJ, Salgado R, Dieci MV, Vingiani A, et al
    Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Ann Oncol. 2019;30:236-242.
    >> Share

  135. KIM H, Son S
    Therapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer.
    Ann Oncol. 2019;30 Suppl 1:i8.
    >> Share

  136. SON S, Kim H, Shin I
    Matricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer.
    Ann Oncol. 2019;30 Suppl 1:i8.
    >> Share

  137. YAP YS, Ho D, Ng RC, Chan CH, et al
    Detection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens.
    Ann Oncol. 2019;30 Suppl 1:i10.
    >> Share

    January 2019
  138. CONDORELLI R, Mosele F, Verret B, Bachelot T, et al
    Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Ann Oncol. 2019 Jan 31. pii: 5305018. doi: 10.1093.
    >> Share

  139. ROBSON ME, Tung N, Conte P, Im SA, et al
    OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Ann Oncol. 2019 Jan 23. pii: 5299440. doi: 10.1093.
    >> Share

  140. DELALOGE S, Cella D, Ye Y, Buyse M, et al
    Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial.
    Ann Oncol. 2019 Jan 23. pii: 5299438. doi: 10.1093.
    >> Share

  141. DIECI MV, Conte P, Bisagni G, Brandes AA, et al
    Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
    Ann Oncol. 2019 Jan 17. pii: 5290085. doi: 10.1093.
    >> Share

  142. CORTES J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, et al
    Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
    Ann Oncol. 2019 Jan 9. pii: 5281258. doi: 10.1093.
    >> Share

  143. BASELGA J, Manikhas A, Cortes J, Llombart A, et al
    Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
    Ann Oncol. 2019 Jan 9. pii: 5281256. doi: 10.1093.
    >> Share

  144. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2019 Jan 9. pii: 5281259. doi: 10.1093.
    >> Share

  145. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2019 Jan 9. pii: 5281263. doi: 10.1093.
    >> Share

  146. CURIGLIANO G, Burstein HJ, P Winer E, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2019 Jan 9. pii: 5281261. doi: 10.1093.
    >> Share

  147. WU Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, et al
    Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
    Ann Oncol. 2019 Jan 9. pii: 5281255. doi: 10.1093.
    >> Share

    December 2018
  148. LUEN SJ, Salgado R, Dieci MV, Vingiani A, et al
    Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neo-adjuvant chemotherapy.
    Ann Oncol. 2018 Dec 27. pii: 5262220. doi: 10.1093.
    >> Share

    November 2018
  149. ADAMS S, Schmid P, Rugo HS, Winer EP, et al
    Pembrolizumab Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: Cohort A of the Phase 2 KEYNOTE-086 Study.
    Ann Oncol. 2018 Nov 26. pii: 5209693. doi: 10.1093.
    >> Share

  150. ADAMS S, Loi S, Toppmeyer D, Cescon DW, et al
    Title: Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase 2 KEYNOTE-086 Study.
    Ann Oncol. 2018 Nov 26. pii: 5209695. doi: 10.1093.
    >> Share

  151. EVRON E, Ben-David AM, Goldberg H, Fried G, et al
    Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers with Early Stage Breast Cancer.
    Ann Oncol. 2018 Nov 23. pii: 5200725. doi: 10.1093.
    >> Share

  152. SOKOL ES, Feng YX, Jin DX, Basudan A, et al
    Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
    Ann Oncol. 2018 Nov 13. pii: 5181087. doi: 10.1093.
    >> Share

  153. FOUKAKIS T
    Carboplatin in the neoadjuvant treatment of triple-negative breast cancer - ready for prime time?
    Ann Oncol. 2018 Nov 5. pii: 5160131. doi: 10.1093.
    >> Share

    October 2018
  154. MATHEW A, Erqou S
    Can Estrogen Receptor Status Predict for Shorter Duration of Adjuvant Trastuzumab in Early-Stage Breast Cancer?
    Ann Oncol. 2018 Oct 24. pii: 5144112. doi: 10.1093.
    >> Share

  155. MATIKAS A, Foukakis T, Moebus V, Greil R, et al
    Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients.
    Ann Oncol. 2018 Oct 24. pii: 5144113. doi: 10.1093.
    >> Share

  156. KOK M, Winer E, Loi S
    Passion for Immune checkpoint blockade in triple negative breast cancer? Comment on the IMpassion130 study.
    Ann Oncol. 2018 Oct 23. pii: 5142540. doi: 10.1093.
    >> Share

  157. COTTU P, D'Hondt V, Dureau S, Lerebours F, et al
    Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
    Ann Oncol. 2018 Oct 11. pii: 5126820. doi: 10.1093.
    >> Share

  158. BRANDAO M, Ignatiadis M
    CDK4/6 inhibitors as neoadjuvant treatment in breast cancer - what can we learn?
    Ann Oncol. 2018 Oct 10. pii: 5126228. doi: 10.1093.
    >> Share

    September 2018
  159. SZEKELY B, Bossuyt V, Li X, Wali VB, et al
    Immunological differences between primary and metastatic breast cancer.
    Ann Oncol. 2018 Sep 10. pii: 5094494. doi: 10.1093.
    >> Share

    August 2018
  160. CHEN X, Li Y, Ouyang T, Li J, et al
    Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
    Ann Oncol. 2018 Aug 27. pii: 5079839. doi: 10.1093.
    >> Share

  161. ETTL J, Quek RGW, Lee KH, Rugo HS, et al
    Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
    Ann Oncol. 2018 Aug 15. pii: 5074207. doi: 10.1093.
    >> Share

    July 2018
  162. CARDOSO F, Senkus E, Costa A, Papadopoulos E, et al
    4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
    Ann Oncol. 2018 Jul 19. pii: 5055519. doi: 10.1093.
    >> Share

  163. ROBSON M
    Selecting patients with triple negative breast cancer for platinum-based therapy: we still haven't found what we're looking for.
    Ann Oncol. 2018 Jul 4. pii: 5048958. doi: 10.1093.
    >> Share

    June 2018
  164. BRUSSELAERS N, Tamimi RM, Konings P, Rosner B, et al
    Different menopausal hormone regimens and risk of breast cancer.
    Ann Oncol. 2018 Jun 18. pii: 5039890. doi: 10.1093.
    >> Share

  165. DIOSSY M, Reiniger L, Sztupinszki Z, Krzystanek M, et al
    Breast cancer brain metastases show increased levels of genomic aberration based homologous recombination deficiency scores relative to their corresponding primary tumors.
    Ann Oncol. 2018 Jun 18. pii: 5039891. doi: 10.1093.
    >> Share

  166. ZHANG J, Lin Y, Sun XJ, Wang BY, et al
    Biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    Ann Oncol. 2018 Jun 14. pii: 5037891. doi: 10.1093.
    >> Share

  167. IGNATIADIS M, Litiere S, Rothe F, Riethdorf S, et al
    Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.
    Ann Oncol. 2018 Jun 11. pii: 5035683. doi: 10.1093.
    >> Share

  168. MALORNI L, Curigliano G, Minisini AM, Cinieri S, et al
    Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
    Ann Oncol. 2018 Jun 11. pii: 5035682. doi: 10.1093.
    >> Share

  169. YARDLEY DA, Coleman R, Conte P, Cortes J, et al
    nab-Paclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial.
    Ann Oncol. 2018 Jun 6. pii: 5033593. doi: 10.1093.
    >> Share

  170. POGGIO F, Bruzzone M, Ceppi M, Ponde NF, et al
    Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Ann Oncol. 2018 Jun 4. pii: 5026316. doi: 10.1093.
    >> Share

    May 2018
  171. CURIGLIANO G, Burstein HJ, Winer EP, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2018 May 3. pii: 4992289. doi: 10.1093.
    >> Share

  172. GAGE MM, Mylander WC, Rosman M, Fujii T, et al
    Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
    Ann Oncol. 2018;29:1280-1285.
    >> Share

  173. LIU C, Wang L, Zhuang J, Liu L, et al
    Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.
    Ann Oncol. 2018;29:1329-1330.
    >> Share

    April 2018
  174. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Ann Oncol. 2018 Apr 27. pii: 4989216. doi: 10.1093.
    >> Share

  175. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2018 Apr 26. pii: 4986930. doi: 10.1093.
    >> Share

  176. GEFFEN DB
    Should decisions on adding adjuvant chemotherapy in early stage ER positive breast cancer be based on gene expression testing or clinicopathologic factors or both?
    Ann Oncol. 2018 Apr 4. pii: 4959909. doi: 10.1093.
    >> Share

  177. CRUZ C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, et al
    RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.
    Ann Oncol. 2018 Apr 4. pii: 4959904. doi: 10.1093.
    >> Share

    February 2018
  178. CORTES J, Perez-Garcia J, Levy C, Gomez Pardo P, et al
    Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
    Ann Oncol. 2018 Feb 21. pii: 4897992. doi: 10.1093.
    >> Share

  179. MARTIN M, Campone M, Bondarenko I, Sakaeva D, et al
    Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
    Ann Oncol. 2018 Feb 10. pii: 4852792. doi: 10.1093.
    >> Share

    January 2018
  180. TAN WW, Hillman DW, Salim M, Northfelt DW, et al
    N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
    Ann Oncol. 2018 Jan 29. pii: 4829660. doi: 10.1093.
    >> Share

  181. BARECHE Y, Venet D, Ignatiadis M, Aftimos P, et al
    Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Ann Oncol. 2018 Jan 22. pii: 4819112. doi: 10.1093.
    >> Share

  182. HARTMAIER RJ, Trabucco SE, Priedigkeit N, Chung JH, et al
    Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer.
    Ann Oncol. 2018 Jan 19. pii: 4817340. doi: 10.1093.
    >> Share

  183. ABBOSH C, Swanton C, Birkbak NJ
    Circulating tumor DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.
    Ann Oncol. 2018 Jan 17. pii: 4815740. doi: 10.1093.
    >> Share

  184. TURNER NC, Finn RS, Martin M, Im SA, et al
    Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases.
    Ann Oncol. 2018 Jan 11. pii: 4802189. doi: 10.1093.
    >> Share

  185. SOMASHEKHAR SP, Sepulveda MJ, Puglielli S, Norden AD, et al
    Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board.
    Ann Oncol. 2018 Jan 9. pii: 4781689. doi: 10.1093.
    >> Share

  186. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2018 Jan 2. pii: 4782676. doi: 10.1093.
    >> Share

    December 2017
  187. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    >> Share

  188. SHARMA P, Barlow WE, Godwin AK, Pathak H, et al
    Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313).
    Ann Oncol. 2017 Dec 23. pii: 4774220. doi: 10.1093.
    >> Share

  189. SWAIN SM, Ewer MS, Viale G, Delaloge S, et al
    Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
    Ann Oncol. 2017 Dec 15. pii: 4748818. doi: 10.1093.
    >> Share

  190. CONDORELLI R, Spring L, O'Shaughnessy J, Lacroix L, et al
    Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
    Ann Oncol. 2017 Dec 11. pii: 4725051. doi: 10.1093.
    >> Share

  191. GENNARI A, Sun Z, Hasler-Strub U, Colleoni M, et al
    A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
    Ann Oncol. 2017 Dec 8. pii: 4710349. doi: 10.1093.
    >> Share

  192. PALUCH-SHIMON S, Peccatori FA
    BRCA 1 and 2 mutation status: the elephant in the room during oncofertility counseling for young breast cancer patients.
    Ann Oncol. 2017 Dec 5. pii: 4693825. doi: 10.1093.
    >> Share

    November 2017
  193. FRANCIS PA
    Male Breast Cancer: Pink Ribbon Blues.
    Ann Oncol. 2017 Nov 20. doi: 10.1093.
    >> Share

  194. BUISSERET L, Pommey S, Allard B, Garaud S, et al
    Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
    Ann Oncol. 2017 Nov 14. doi: 10.1093.
    >> Share

  195. SESTAK I, Smith SG, Howell A, Forbes JF, et al
    Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
    Ann Oncol. 2017 Nov 6. doi: 10.1093.
    >> Share

  196. PATEL R, Maxwell S, Yan D, Dressler EV, et al
    Medical Oncologists' Perception of Anti-Estrogen Therapy Benefit in Premenopausal Women with Hormone Receptor-Positive Early Breast Cancer.
    Ann Oncol. 2017 Nov 2. doi: 10.1093.
    >> Share

    October 2017
  197. KOK M
    LAG-3: another brake to release in breast cancer?
    Ann Oncol. 2017 Oct 30. doi: 10.1093.
    >> Share

  198. CARDOSO F, Bartlett JMS, Slaets L, van Deurzen CHM, et al
    Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    >> Share

  199. BLACKWELL K, Gascon P, Krendyukov A, Gattu S, et al
    Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase 3, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppr
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    >> Share

  200. CRISCITIELLO C, Bayar MA, Curigliano G, Symmans FW, et al
    A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer.
    Ann Oncol. 2017 Oct 25. doi: 10.1093.
    >> Share

  201. MOBUS V, Jackisch C, Lueck HJ, du Bois A, et al
    Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial.
    Ann Oncol. 2017 Oct 24. doi: 10.1093.
    >> Share

  202. NUCIFORO P, Pascual T, Cortes J, Llombart-Cussac A, et al
    A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Ann Oncol. 2017 Oct 12. doi: 10.1093.
    >> Share

  203. NABIEVA N, Kellner S, Fehm T, Haberle L, et al
    Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    >> Share

  204. LAMBERTINI M, Goldrat O, Ferreira AR, Dechene J, et al
    Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    >> Share

  205. FRIBBENS C, Garcia Murillas I, Beaney M, Hrebien S, et al
    Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
    Ann Oncol. 2017 Oct 4. doi: 10.1093.
    >> Share

  206. FUJII T, Kogawa T, Dong W, Sahin AA, et al
    Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.
    Ann Oncol. 2017;28:2420-2428.
    >> Share

    September 2017
  207. HAN HS, Dieras V, Robson M, Palacova M, et al
    Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.
    Ann Oncol. 2017 Sep 29. doi: 10.1093.
    >> Share

  208. BURUGU S, Gao D, Leung S, Chia SK, et al
    LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    >> Share

  209. CURIGLIANO G, Burstein HJ, Winer EP, Gnant M, et al
    Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    >> Share

  210. KIROVA YM, Carroll S, Fourquet A, Offersen B, et al
    The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology.
    Ann Oncol. 2017 Sep 22. doi: 10.1093.
    >> Share

  211. CHAJES V, Assi N, Biessy C, Ferrari P, et al
    A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    >> Share

  212. MESSINA C, Messina M, Zanardi E
    Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    >> Share

  213. BUTTERBAUGH ST, Patel R, Romond EH, Mathew A, et al
    Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    >> Share

  214. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    De-escalation strategies in HER2-positive early breast cancer (EBC): Final analysis of the WSG-ADAPT HER2+/HR- phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekl
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    >> Share

  215. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    >> Share

  216. HAMY AS, Pierga JY, Sabaila A, Laas E, et al
    Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
    Ann Oncol. 2017;28:2233-2240.
    >> Share

  217. BERNICHON E, Vallard A, Wang Q, Attignon V, et al
    Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
    Ann Oncol. 2017 Sep 1. doi: 10.1093.
    >> Share

  218. VAN BOCKSTAL M, Libbrecht L, Floris G, Lambein K, et al
    Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?
    Ann Oncol. 2017;28:2317.
    >> Share

    August 2017
  219. CHUNG JH, Pavlick D, Hartmaier R, Schrock AB, et al
    Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Ann Oncol. 2017 Aug 31. doi: 10.1093.
    >> Share

    February 2017
  220. PRUNERI G, Lazzeroni M, Bagnardi V, Tiburzio GB, et al
    The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
    Ann Oncol. 2017;28:321-328.
    >> Share

  221. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    >> Share

  222. MAKKOUK A, Sundaram V, Chester C, Chang S, et al
    Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.
    Ann Oncol. 2017;28:415-420.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016